Floatz logo

Silymarin

Parkinson Disease

Tanta UniversityPhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
65/ 100

Competitive context

255 Active assets in the Parkinson Disease cohort.

Asset / SponsorPhaseRating
Safinamide
Zambon SpA
Phase 4A
Cvt-301
Acorda Therapeutics
Phase 3A
Pardoprunox
Abbott Products
Phase 3BBB
Tvp-1012
Guangzhou Henovcom Bioscience Co. Ltd.
Phase 4BBB
Istradefylline
Georgetown University
Phase 4BBB

View all 50 →

Same molecule, other indications

Silymarin is also rated in:

metabolic dysfunction-associated steatotic liver diseaseDormant
BB
Indicative ·
69 / 100
View asset →
colorectal cancerDormant
B
Indicative ·
63 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →